Top Stories on Drug Topics®

Did you miss the top Drug Topics® stories this month? Catch up on these remarkable stories today.

ten. Launch of Lucentis’ first interchangeable biosimilar

Cimerli can be used for all 5 indications. No pricing information has been released.

9. Become the pharmacy of the future with technological solutions

Technology is reshaping the way health care is delivered. From the doctor’s office to the pharmacy, a host of innovative ideas and solutions are poised to change the way pharmacies interact with their customers and patients.

8. Flu vaccination and hospitalized elderly with cardiovascular disease: what are the benefits?

A study published in the International Journal of Infectious Diseases found that influenza vaccines reduced in-hospital deaths and recurrent hospitalizations in older adults hospitalized with cardiovascular disease.

seven. Black patients have a higher risk of vision loss after a diagnosis of glaucoma

New research examines disparities in vision loss in glaucoma cases.

6. Ping Pong Pendulum

A pharmacist reflects on how prescribing behaviors have changed over the years and the potential for stigma associated with providing buprenorphine to patients who need it.

5. Vivjoa approved for recurrent vulvovaginal candidiasis

Oteseconazole is a treatment option for people living with a previously unmet medical need.

4. Optum joins other affordable insulin providers

The company will provide uninsured patients nationwide with a way to obtain the drug at a much more affordable price.

3. Probiotics for the prevention of pediatric antibiotic-associated diarrhea

Evidence for the relationship between probiotics and antibiotics is lacking.

2. Pharmacists fight to tackle opioid use disorder

Buprenorphine can only be prescribed by pharmacists with exemptions, limiting access to this necessary treatment for communities.

1. What’s new during the 2022-2023 flu season

Learn about the strains selected for this year’s flu season, changes to flu vaccine recommendations, and newly licensed and upcoming vaccine options.

Comments are closed.